{"log_id": 5692078679365408551, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0, "average": 0.991328, "min": 0.991328}, "location": {"width": 57, "top": 89, "height": 31, "left": 1182}, "words": "文"}, {"probability": {"variance": 0, "average": 0.994988, "min": 0.994988}, "location": {"width": 37, "top": 131, "height": 33, "left": 1193}, "words": "章"}, {"probability": {"variance": 1e-06, "average": 0.998604, "min": 0.996516}, "location": {"width": 157, "top": 162, "height": 28, "left": 201}, "words": "无药物相互作用"}, {"probability": {"variance": 0.000266, "average": 0.99514, "min": 0.907897}, "location": {"width": 799, "top": 212, "height": 46, "left": 241}, "words": "临床试验发现,依那西普与糖皮质激素、水杨酸盐类药物(除柳氮磺胺吡啶外)、"}, {"probability": {"variance": 0.00026, "average": 0.993935, "min": 0.914849}, "location": {"width": 857, "top": 262, "height": 44, "left": 196}, "words": "非甾体抗炎药( NSAIDS)、镇痛药或甲氨蝶呤合并使用时未见药物相互作用。(疫苗使"}, {"probability": {"variance": 3e-06, "average": 0.998625, "min": 0.994207}, "location": {"width": 204, "top": 312, "height": 30, "left": 194}, "words": "用参见“注意事项”"}, {"probability": {"variance": 2.5e-05, "average": 0.99836, "min": 0.969835}, "location": {"width": 814, "top": 361, "height": 45, "left": 235}, "words": "未发现与地高辛或华法林合并用药时出现有临床意义的药代动力学药物药物相互"}, {"probability": {"variance": 5e-06, "average": 0.997372, "min": 0.99511}, "location": {"width": 46, "top": 413, "height": 24, "left": 191}, "words": "作用"}, {"probability": {"variance": 1.3e-05, "average": 0.996018, "min": 0.989399}, "location": {"width": 97, "top": 511, "height": 27, "left": 190}, "words": "[药物过量"}, {"probability": {"variance": 2.5e-05, "average": 0.997638, "min": 0.974697}, "location": {"width": 816, "top": 558, "height": 46, "left": 228}, "words": "在类风湿关节炎患者中进行的临床试验未观察到依那西普的剂量限制性毒性。尚未"}, {"probability": {"variance": 0.000279, "average": 0.993268, "min": 0.916496}, "location": {"width": 861, "top": 607, "height": 47, "left": 182}, "words": "建立依那西普的最大耐受剂量。以16mg/m2(~25mg)每周两次皮下注射给药后观测到"}, {"probability": {"variance": 0.001703, "average": 0.99063, "min": 0.73555}, "location": {"width": 863, "top": 656, "height": 46, "left": 181}, "words": "类风湿关节炎患者的最大静脉负荷剂量为32mg/m2.一位类风湿关节炎患者错误的连续"}, {"probability": {"variance": 3e-06, "average": 0.999035, "min": 0.992031}, "location": {"width": 867, "top": 705, "height": 45, "left": 175}, "words": "3周每周2次自行皮下注射62mg依那西普后未出现不良反应。目前尚未发现依那西普"}, {"probability": {"variance": 0, "average": 0.999454, "min": 0.99858}, "location": {"width": 92, "top": 755, "height": 28, "left": 176}, "words": "的解毒剂"}, {"probability": {"variance": 4.8e-05, "average": 0.983862, "min": 0.973412}, "location": {"width": 111, "top": 854, "height": 27, "left": 172}, "words": "[临床试验]"}, {"probability": {"variance": 3e-06, "average": 0.998693, "min": 0.992134}, "location": {"width": 820, "top": 900, "height": 46, "left": 217}, "words": "本节内容所展示的数据分别来自4个在成年类风湿关节炎患者中进行的随机对照"}, {"probability": {"variance": 2e-06, "average": 0.998856, "min": 0.992969}, "location": {"width": 599, "top": 949, "height": 40, "left": 168}, "words": "临床试验和1个在成年强直性脊柱炎患者中进行的临床试验"}, {"probability": {"variance": 2e-06, "average": 0.999151, "min": 0.995057}, "location": {"width": 185, "top": 999, "height": 29, "left": 169}, "words": "成人类风湿关节炎"}, {"probability": {"variance": 1.8e-05, "average": 0.997491, "min": 0.980978}, "location": {"width": 798, "top": 1048, "height": 42, "left": 235}, "words": "项随机、双盲、安慰剂对照的研究对依那西普的有效性进行了评估。该研究评价"}, {"probability": {"variance": 4.2e-05, "average": 0.997198, "min": 0.974204}, "location": {"width": 865, "top": 1096, "height": 42, "left": 167}, "words": "了234位活动性类风湿关节炎患者,这些患者至少使用了一种但不超过四种改善病情的"}, {"probability": {"variance": 2.5e-05, "average": 0.996887, "min": 0.97438}, "location": {"width": 870, "top": 1143, "height": 46, "left": 163}, "words": "抗风湿药物( DMARD)治疗无效,连续6个月每周2次皮下注射给予10mg或25mg"}, {"probability": {"variance": 3.5e-05, "average": 0.996943, "min": 0.975086}, "location": {"width": 869, "top": 1192, "height": 44, "left": 162}, "words": "依那西普或安慰剂。将这项对照试验的结果以美国风湿病学院(ACR)反应标准对类风"}, {"probability": {"variance": 0, "average": 0.999094, "min": 0.99769}, "location": {"width": 327, "top": 1242, "height": 34, "left": 161}, "words": "湿关节炎改善的百分比进行呈现"}, {"probability": {"variance": 0, "average": 0.765364, "min": 0.765364}, "location": {"width": 35, "top": 1278, "height": 27, "left": 970}, "words": "△"}, {"probability": {"variance": 0.000828, "average": 0.991193, "min": 0.822045}, "location": {"width": 827, "top": 1292, "height": 41, "left": 205}, "words": "在治疗第3个月和第6个月,依那西普治疗患者的ACR20和ACR50反应高于安慰"}, {"probability": {"variance": 0.002544, "average": 0.982729, "min": 0.734284}, "location": {"width": 864, "top": 1340, "height": 43, "left": 159}, "words": "剂对照组(第3个月和第6个月依那西普的ACR20分别为62%和5%,安慰剂的ACR2"}, {"probability": {"variance": 0.00025, "average": 0.994036, "min": 0.921815}, "location": {"width": 872, "top": 1391, "height": 39, "left": 158}, "words": "分别为23%和11%,依那西普的ACR50分别为41%和40%,安慰剂的ACR50分别为"}, {"probability": {"variance": 7.1e-05, "average": 0.996596, "min": 0.951426}, "location": {"width": 872, "top": 1440, "height": 40, "left": 157}, "words": "8%和5%;在所有时间点依那西普与安慰剂的ACR20和ACR50反应进行比较的"}, {"probability": {"variance": 0.000126, "average": 0.994583, "min": 0.942852}, "location": {"width": 870, "top": 1489, "height": 39, "left": 153}, "words": "p<0.01)。接受依那西普治疗的患者中约有15%在3个月和6个月时达到ACR70,与之"}, {"probability": {"variance": 2.2e-05, "average": 0.998031, "min": 0.976888}, "location": {"width": 869, "top": 1538, "height": 39, "left": 156}, "words": "相比,安慰剂治疗组的患者则少于5%。依那西普治疗组的患者中,临床疗效一般在开"}, {"probability": {"variance": 0.001331, "average": 0.99291, "min": 0.766018}, "location": {"width": 873, "top": 1584, "height": 42, "left": 151}, "words": "始治疗后1-2周内出现,并能持续3个月。试验可见剂量效应关系,10mg剂量的疗效"}, {"probability": {"variance": 9.9e-05, "average": 0.992542, "min": 0.965098}, "location": {"width": 161, "top": 1635, "height": 25, "left": 151}, "words": "版本号:20090118"}, {"probability": {"variance": 3.6e-05, "average": 0.994977, "min": 0.982205}, "location": {"width": 177, "top": 1641, "height": 28, "left": 761}, "words": "第15页共31页"}], "language": 3}